

=Quantum BioTarget™ – Investor One-Pager

Quantum BioTarget™ is pioneering a next-generation cancer therapy system that utilizes quantum entangled photons, nanodiamond carriers, and precision-guided alpha radiation (Bi-213) to deliver unprecedented targeting power against tumors — while minimizing collateral damage to healthy cells.

- Photon entanglement used to guide nanodiamonds directly to tumor sites.
- Nova AI performs dual-trigger logic: quantum arrival + biological verification.
- Bi-213 payload released only under precise, AI-validated conditions.
- Adaptive imaging integration using patient-specific MRI/CT scans.
- Fully logged, real-time simulation system tracks photon hits and payload releases.
- 3D animated prototype simulation complete — showing feasibility and logic.
- Provisional Patent Filed: Quantum BioTarget™ | USPTO App #63/851,582
- Founder: Adam Samuel McCombs | Contact: founder@quantumbiotarget.com

Learn more at www.QuantumBioTarget.com — or request a full deck under NDA.